


Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450



6p1642  
Docket No.: 392.1001  
Date: April 25, 2007

In re application of: Hiroyuki ABURATANI et al.  
Serial No.: 10/526,508  
Filed: September 4, 2003  
For: A METHOD FOR DIAGNOSING CANCER BY DETECTING GPC3

Sir:

Transmitted herewith is an **Information Disclosure Statement (2 pages)** in the above-identified application.

[X] Also transmitted herewith are:

[ ] Petition for extension under 37 C.F.R. 1.136

[X] Other: **Form PTO 1449 (1 page)**

**Copies of Cited References (23 pages)**

**Return Receipt Postcard**

[ ] Check(s) in the amount of **\$0.00** is/are attached to cover:

[ ] Filing fee for additional claims under 37 C.F.R. 1.16

[ ] Petition fee for extension under 37 C.F.R. 1.136


[ ] Other:

[X] The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-0552.


[ ] Any filing fee under 37 C.F.R. 1.16 for the presentation of additional claims which are not paid by check submitted herewith.

[X] Any patent application processing fees under 37 C.F.R. 1.17.

[X] Any petition fees for extension under 37 C.F.R. 1.136 which are not paid by check submitted herewith, and it is hereby requested that this be a petition for an automatic extension of time under 37 CFR 1.136.

  
Robert J. Paradiso, Reg. No. 41,240  
DAVIDSON, DAVIDSON & KAPPEL, LLC  
485 Seventh Avenue, 14<sup>th</sup> Floor  
New York, New York 10018  
Tel: (212) 736-1940  
Fax: (212) 736-2427

I hereby certify that the documents referred to as attached therein and/or fee are being deposited with the United States Postal Service as "first class mail" with sufficient postage in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" on April 25, 2007.  
DAVIDSON, DAVIDSON & KAPPEL, LLC

BY:   
Oleg Losevich



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Re: Application of: Hiroyuki ABURATANI et al. Confirmation No. 4237  
Serial No.: 10/526,508  
Filed: September 4, 2003  
For: **A METHOD FOR DIAGNOSING CANCER BY  
DETECTING GPC3**  
Examiner: Catherine JOYCE  
Art Unit: 1642

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

April 25, 2007

**INFORMATION DISCLOSURE STATEMENT**

S I R:

In accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby make of record the documents listed on the accompanying Form PTO-1449 (1 page) for consideration by the Examiner in connection with the examination of the above-identified patent application.

In accordance with 37 C.F.R. § 1.98(a)(2), copies of the listed documents are enclosed. If it is determined that a copy of any of the documents is missing and is required, the Examiner is requested to contact the undersigned so that a copy can be provided.

Applicants respectfully note that the listed documents were cited in the Supplementary European Search Report issued in connection with European Patent Application No. 03 80 9427. A copy of the Search Report is attached as Appendix A.

Applicants respectfully submit that these documents were cited in a communication from the European Patent Office in a counterpart foreign application on March 21, 2007, "no more than three months prior to the filing of the information disclosure statement."

It is respectfully requested that the documents listed on the accompanying Form PTO-1449 (1 page) be considered and made of record.

This Information Disclosure Statement is being submitted before a first Office Action on the merits and lists documents cited "no more than three months prior to the filing of the information disclosure statement." Accordingly, under 37 C.F.R. § 1.97, no fee is believed due. If any fees are due at this time, the Commissioner is authorization to charge such fee to Deposit Account No. 50-0552.

Respectfully submitted,  
DAVIDSON, DAVIDSON & KAPPEL, LLC

By: 

Robert J. Paradise  
Reg. No. 41,240

Davidson, Davidson & Kappel, LLC  
485 Seventh Avenue, 14<sup>th</sup> Floor  
New York, New York 10018  
(212) 736-1940

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 392.1001

SERIAL NO.: 10/526,508

**LIST OF PRIOR ART CITED BY APPLICANT**

(Use several sheets if necessary)

APPLICANT(S): Hiroyuki ABURATANI et al.

FILING DATE: September 4, 2003

GROUP: 1642

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AI							
	AJ							
	AK							
	AL							
	AM							

**OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)**

	AN	ZHU Z-W ET AL: "Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders" GUT, BRITISH MEDICAL ASSOCIATION, LONDON, GB, vol. 48, 17 October 2001 (2001-10-17), pages 558-564, XP002959808 ISSN: 0017-5749
	AO	KLEEFF J H ET AL: "Glypican-3 is a potential tumor marker for hepatocellular carcinoma" GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, US, vol. 118, no. 4, SUPPL 2, PART 1, 2000, page A261, ABSTRACT 1501, XP002959809 ISSN: 0016-5085
	AP	NACKAERTS K ET AL: "HEPARAN SULFATE PROTEOGLYCAN EXPRESSION IN HUMAN LUNG-CANCER CELLS" INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 74, 1997, pages 335-345, XP002925654 ISSN: 0020-7136

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.